RxWeekly – 1/28 – 2/4
March 7, 2020
Hello and Happy Thursday! Welcome to RxWeekly.
I’m Anyssa Garza with the most recent health news and FDA alerts.
This week, the FDA approved Halaven patients with liposarcoma who have already received
chemotherapy that contained an anthracycline drug, and whose cancer cannot be removed by
surgery or is metastatic. Halaven was approved in 2010 for advanced breast cancer. Dr. Richard
Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center
for Drug Evaluation and Research, states “The clinical trial data the FDA reviewed indicates
that Halaven increased overall survival by approximately seven months, offering patients
a clinically meaningful drug.” Switching gears, the FDA also approved Zepatier
with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes
1 and 4 infections in adult patients. Dr. Edward Cox, director of the Office of Antimicrobial
Products in the FDA’s Center for Drug Evaluation and Research, states “The approval Zepatier
provides another oral treatment option for patients without requiring use of interferon.